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Background: Chronic obstructive pulmonary disease (COPD) is characterized by an enhanced
and persistent innate and acquired immune response to tobacco smoking. Myeloid-derived sup-
pressor cells (MDSCs) modulate T-cell responses by down-modulating the T cell receptor z chain
(TCR z) through the catabolism of L-arginine. The effects of smoking on MDSCs and their poten-
tial participation in COPD immunopathogenesis have not been explored so far.
Methods: To investigate it, we compared the level of circulating Lineage-/HLA-DR-/CD33þ/
CD11bþ MDSCs, the serum concentration of arginase I (ARG I) and the expression of peripheral
T-cell receptor z chain (TCR z) in never smokers, smokers with normal spirometry and COPD
patients. Flow cytometry was used to quantify circulating MDSCs and TCR z expression. Serum
ARG I levels were determined by ELISA.
Results: The main findings of this study were that: (1) current smoking upregulates and acti-
vates circulating MDSCs both in smoker controls and COPD patients; and, (2) at variance with, Chronic obstructive pulmonary disease; MDSCs, Myeloid derived suppressor cells; PBMCs, Peripheral
ll receptor z chain.
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1896 S. Scrimini et al.the smokers with normal spirometry, in patients with COPD this effect persists after quitting
smoking and is accompanied by a significant and specific down-regulation of the TCR z chain
expression in circulating T lymphocytes.
Conclusion: Smoking modulates circulating MDSCs. Their regulation appears altered in patients
with COPD.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by an enhanced inflammatory response of the lung
to noxious particles or gases [1], where both innate and
adaptive immunity participate [2]. Epithelial cells, macro-
phages and neutrophils are activated by irritants such as
cigarette smoke and, as a result, there is a significant in-
crease of dendritic cells subsets, activated T cells (CD4þ
and CD8þ T cells), and B cells in the lung parenchyma of
COPD patients [3]. This inflammatory cell infiltration per-
sists after smoking cessation, suggesting a self-
perpetuating process [4]. All in all, these findings support
that the immune response is deregulated in those smokers
who develop COPD [3]. Several pieces of evidence support
this contention [5e8]. First, abnormalities in forkhead box
P3 (FOXP3)þ regulatory T (Treg) cells, which are essential
for the maintenance of self-tolerance and immune ho-
meostasis by suppressing T cell effector activity [9], have
been reported in COPD patients [5e7]. Second, the gd
CD8þ T lymphocytes, a T cell population with immunoreg-
ulatory properties [10], are reduced in both the lungs and
peripheral blood of COPD patients as compared to smokers
with normal lung function [8].
The so-called myeloid-derived suppressor cells (MDSCs)
are a heterogeneous group of myeloid cells that include
immature macrophages, granulocytes, dendritic cells (DCs)
and other myeloid cells at earlier stages of differentiation
with a remarkable ability to repress T-cell responses [11].
MDSCs suppress T-cell function by down-regulating the T-
cell receptor z chain (TCR z), without affecting the rest of
TCR subunits (CD3 ε and aß) through the modulation of L-
arginine metabolism [12,13]. Human MDSCs release argi-
nase I (ARG I) from cytoplasmic granules into the micro-
environment and circulation, where it catabolizes L-
arginine and induces T-cell dysfunction [14].
Initially described as one of the mechanisms used by
tumor cells to escape the immune system response [15],
growing evidence indicates that MDSCs also regulate the
immune response in a range of inflammatory non-malignant
conditions [11,16]. Although in patients with a variety of
malignancies MDSCs are mostly identified as Lin/HLA-DR/
CD33þ CD11bþ, this MDSCs phenotype has not been studied
in human inflammatory non-malignant settings [17]. Their
response to smoking and their potential role in the patho-
biology of COPD has not been explored so far. To investigate
it, we compared the level of circulating MDSCs in never
smokers, smokers with normal spirometry and COPD pa-
tients. Besides, we determined the serum levels of ARG I to
assess the activation of circulating MDSCs [14,18], and the
expression of TCR z in peripheral lymphocytes.Materials and methods
Study design and ethics
This is a cross-sectional, descriptive, comparative and
controlled study. All participants signed their informed
consent after being aware of the nature and objectives of
the study. The project was approved by the Ethics Com-
mittee of the Balearic Islands in Spain.
Participants
Participants were selected from individuals referred to the
pulmonary function laboratory of our institution or primary
care clinics. The diagnosis of COPD was established ac-
cording to the GOLD recommendations [19]. All COPD pa-
tients were clinically stable and had not had any
exacerbation or change of therapy for, at least, the last 3
months. Only smokers (with normal spirometry) and COPD
patients with a cumulative smoking exposure of, at least,
10 pack-years were selected for the study. Former smokers
were defined by having fully quitted smoking for at least 1
year before participating in the study. No participant was
receiving oral steroids, immunomodulatory drugs and/or
antibiotics. Subjects with atopic diseases, asthma, auto-
immune disorders, malignancy, heart failure, kidney dis-
eases and infectious diseases were excluded.
Lung function
Forced spirometry (before and after bronchodilation) was
obtained (Micro 6000 Spirometer, Medisoft, France)
following international guidelines [20]. The severity of
airflow limitation was established on post-bronchodilator
results according to the GOLD recommendations [19].
Reference values were those of a Mediterranean population
[21].
Peripheral blood sampling and processing
Blood samples were obtained by peripheral venipuncture,
and collected in three different tubes: (1) 5 ml in non-
heparinized tubes for serum measurements. Blood was
allowed to clot and centrifuged 15 min at 3000 rpm at 4 C.
Then, serum was aliquoted and stored at 70 C until
analysis; (2) 10 ml in sodium heparin tubes for isolation of
peripheral blood mononuclear cells (PBMCs) as described
below; and, (3) 5 ml in EDTA tubes for identification of T
cell subpopulations.
Myeloid derived suppressor cells in COPD 1897White blood cell count
Absolute and differential cell counts in blood were per-
formed using a CELL-DYN Sapphire automatic analyzer
(Abbot, USA) following manufacturer’s instruction.
Circulating T-cell subpopulations
T-cells subpopulations were evaluated in whole blood
samples incubated with combinations of anti-CD3-PE, anti-
CD4-PE-Cy5 and anti-CD8-FITC conjugated monoclonal an-
tibodies (BD Pharmingen, NJ, USA) for 30 min at room
temperature in the dark. Then, lysing solution (BD FACS,
BD Biosciences) was added and cells were washed and re-
suspended in 1 phosphate-buffered saline (PBS) (Dulbec-
co’s PBS, PAA Laboratory, Pasching, Austria).
Quantification of circulating MDSCs
MDSCs were identified in PBMCs isolated by gradient
centrifugation (lymphocyte separation medium, PAA Labo-
ratory, Pasching, Austria), washed three times and re-
suspended in PBS. After that, PBMCs were incubated with
a combination of anti-lineage cocktail 2 (a mixture of
monoclonal antibodies against CD3, CD14, CD19, CD20 and
CD56) e FITC (BD Biosciences, San Jose, CA), anti-MHC class
II (HLA-DR)-ECD (Beckman Coulter, France), anti-CD33-PE-
Cy5 and anti-CD11b-PE (BD Pharmingen, NJ, USA) conju-
gated monoclonal antibodies. After incubation for 30 min at
room temperature in the dark, cells were fixed, washed and
re-suspended in PBS for analysis. MDSCs were identify as a
population of cells lacking the expression of CD3, CD14,
CD19, CD20, CD56 (included in the lineage cocktail 2) and
MHC class II (HLA-DR) molecules and expressing the com-
mon myeloid marker CD33 and the ß2 integrin CD11b: Lin
/
HLA-DR/CD33þ/CD11bþ (Fig. 1) [11,17,18,22].
Serum levels of arginase I (ARG I)
ARG I serum levels were quantified by ELISA using a specific
human arginase I (liver type) antibody (BioVendor, Brno,
Czech Republic). Mean absorbance was calculated from the
standard curve.
TCR z and CD3 ε chain expression
Intracellular TCR z was analyzed in PBMCs that were pre-
viously incubated with an anti-CD3 ε-FITC (BD Pharmingen)
monoclonal antibody. After that, samples were fixed, per-
meabilized and stained with an anti-TCR z-PE (Abcam,
Cambridge, UK) monoclonal antibody using the fixation/
permeabilization kit (e-Biosciences) according to manu-
facturer’s instructions. TCR z and CD3 ε expression was
determined on total CD3þ cells.
Flow cytometry
Analysis of T-cell subpopulations, MSDCs and the expression
of TCR z and TCR ε chains was carried out in an Epics XL-MCL
flow cytometer (Beckman Coulter) using the Expo32 ADCsoftware (Beckman Coulter). The percentage of T-cell sub-
populations and MSDC were referred to the total amount of
lymphocytes and PBMCs respectively. TCR z and CD3 ε were
evaluated as mean fluorescence intensity (MFI) of both
molecules in a previously gate of CD3þ T-lymphocytes.
Statistical analysis
According to previous publications showing that the per-
centage of immature myeloid cells (IMCs) constitute 0.5% of
peripheral blood mononuclear cells in healthy individuals
[11], we calculated that a minimum of 25 subjects per
group was required to recognize as statistically significant a
difference 0.3%, accepting an a risk of 0.05 (two-sided)
and a ß risk of 0.20.
Results of continuous variables are shown as
mean  standard error of the mean (SEM) or median [range]
depending if they were normally distributed or not. Results
of qualitative variables are presented as frequencies and
percentages. A one-way ANOVA or the KruskaleWallis test,
with Bonferroni post hoc contrasts, were used to test the
statistical significance of differences between groups ac-
cording to the distribution of the variable. A p value lower
than 0.05 was considered statistically significant.
Results
Clinical data
We studied 53 patients with COPD, 32 smokers with normal
spirometry and 27 never-smokers. Table 1 summarizes the
main anthropometric, clinical and functional characteris-
tics of participants. COPD patients were older than smokers
with normal spirometry and included more men than the
other two groups (p < 0.05). However, there was no dif-
ference in age between former smokers with normal
spirometry (mean  SE: 61.9  3.2) and COPD subjects
(p > 0.05). Cumulative smoking exposure (pack-yr.) was
greater in COPD than in smokers with normal lung function.
Airflow limitation in patients with COPD ranged from mild
(26.4%) to moderate (39.6%), severe (24.5%) or very severe
(9.4%). By design, spirometry was normal in the two control
groups. Among COPD subjects, 23 (43%) were treated with
the combination of inhaled corticosteroids (ICS) and long-
acting b2 -agonists, while 15 (8%) were using long- acting
broncodilators alone. No significant differences in comor-
bidities as expressed by the Charlson index were found
among groups, although it tended to be higher in smokers
without COPD. Table 2 shows the absolute and differential
white blood cell counts in the three groups of participants.
Total leukocyte count was higher in COPD and smokers.
Patients with COPD showed higher neutrophil and lower
lymphocytes percentages than smokers with normal
spirometry and non-smokers. There was no difference in
CD4 and CD8 T lymphocytes percentages between groups.
Circulating MDSCs
As shown in Fig. 2 (panel A) the percentage of circulating
MDSCs was higher in COPD patients (0.32% [0.04e1.69%])
Figure 1 Representative dot plots of MDSCs from (A) a control never smoker and (B) a COPD patient. A1 represents the HLA-DR
negative, lineage negative population and A2 MDSCs (Lin/HLA-DR/CD33þ/CD11bþ cells).
1898 S. Scrimini et al.than in non-smokers (0.21% [0e0.67%], pZ 0.003). Values in
smokers (0.21% [0e1.25%]) were not statistically different
vs. non-smoking controls or COPD patients. Fig. 2, panel B,
presents these same results by smoking status (current vs.Table 1 Clinical and functional characteristics of participants.
Non-smokers P valu
No. of Patients 27
Age, years 61.5  1.7 0.9
Males, n (%) 13 (48%) 0.1




Years since quitting e
Smoking history, pack-years e e
Charlson index 0.3  0.1 0.07
Inhaled steroid users, n (%) e
BMI (kg/m2) 27.1  0.8 1.0
FEV1 (L) 2.9  0.1 1.0
FEV1% reference 104  2.9 0.13
FEV1/FVC, % 76  0.9 1.0
Data are presented as n or mean  SEM. COPD, chronic obstructive p
FVC, forced vital capacity; BMI, body mass index. **P < 0.01; ***P <former). The proportion of circulating MDSCs in current
smokers with normal lung function was significantly higher
than in former smoker controls, indicating that tobacco
smoking is associated with increased circulating MDSCse Smokers P value COPD patients
32 53
55.6  1.6 0.001 65.2  1.2
20 (62%) 0.01 43 (81%) **
e e
22 (69) 24 (45)
10 (31) 29 (55)
16.2  3.8 0.8 13.5  2
37.8  3.9 0.01 53.4  3.6
0.7  0.1 0.1 0.5  0.1
e 23 (43)
28.2  1 1.0 27.8  0.8
2.9  0.1 <0.001 1.7  0.09***
94  2.6 <0.001 61  3.1 ***
76  0.6 <0.001 52  1.2***
ulmonary disease; FEV1, forced expiratory volume in one second;
0.001 COPD vs non-smokers
Table 2 Absolute and differential cell counts in blood.
Non smokers P value Smokers P value COPD patients
Total leukocytes  103/mL 5.5  0.2 <0.001 7.3  0.3 1.0 7.6  0.2***
Neutrophils, % 55.1  1.5 0.9 57.7  1.5 0.01 62.9  1**
Lymphocytes, % 33.7  1.4 1.0 31.3  1.4 0.01 26.3  1**
Monocytes, % 8  0.4 0.75 7.5  0.3 0.61 7.9  0.3
CD4 lymphocytes, % 34  1.6 1.0 34  1.9 1.0 35  1.2
CD8 lymphocytes, % 18.6  1.5 1.0 19.9  1.4 1.0 19  1.2
Data are presented as mean  SEM. COPD, chronic obstructive pulmonary disease. **P < 0.01; ***P < 0.001 COPD vs non smokers.
Myeloid derived suppressor cells in COPD 1899levels. Interestingly, former smokers with COPD maintained
similar levels than current COPD smokers (Fig. 2, panel B),
supporting their involvement in COPD ethiopathogenesis in-
dependent of tobacco smoking. In patients with COPDwe did
not find any significant relationship between the proportion
of circulating MDSC and the severity of airflow limitation
(Fig. 2, panel C) or treatment with inhaled corticosteroids
(ICS) (0.38% [0.06e1.54%] patients with ICS vs. 0.24%
[0.04e1.69%] patients without ICS).
Serum concentration of arginase I
The serum concentration of ARG I (Fig. 3, panel A) was
similar and significantly higher in smokers and COPD pa-
tients as compared with non-smokers. Differences were
unchanged according to smoking status, although values
tended to decrease in former smokers with normal
spirometry (Fig. 3, panel B). We did not find any significantFigure 2 Panel A: box plot of MDSCs (expressed as % of mononucle
present the same data by smoking status and GOLD stage respectirelationship between the serum levels of ARG I levels and
the degree of airflow limitation or treatment with inhaled
corticosteroids in COPD patients (data not shown).Expression of TCR z and CD3 ε chains
TCR z and CD 3 ε expression levels were measured in the
last 9 never smokers, 10 current smokers with normal
spirometry, and 10 COPD patients included in each group
respectively with no additional selection criteria. Clinical
and demographic characteristics of these subjects were
similar to those of the entire population, except that there
were no differences in age and smoking exposure (Table 1).
Fig. 4 (panels A and C) shows that z chain expression was
significantly down-regulated in T lymphocytes of COPD
patients as compared with both non-smokers (p Z 0.01)
and smokers (p Z 0.005) controls. By contrast, the CD3 εar cells) in the three groups of subjects studied. Panels B and C
vely. For further explanations, see text.
Figure 3 Panel A: box plot of the serum concentration of arginase I (ng/mL) in the three groups of subjects studied. Panel B
presents the same data by smoking status. For further explanations, see text.
1900 S. Scrimini et al.chain signal intensity was similar in the three groups of
subjects studied (Fig. 4, panel B).
Discussion
The main findings of this study are that: (1) current smoking
upregulates (Fig. 2) and activates (Fig. 3) circulating MDSCs;
(2) this effect is not amplified in smokers with COPD, but in
contrast to smokers with normal spirometry, in these pa-
tients it persists despite quitting smoking (Figs. 2 and 3); and,
(3) in COPD patients, but not in smokers with normal
spirometry, the activation of MDSCs is accompanied by aFigure 4 Mean (SEM) values of TCR z (panel A) and CD3 ε (panel
function and COPD patients. Panel C shows two representative hi
histogram) and a COPD patient (grey histogram). White histogram
body. MFI: mean fluorescence intensity.significant and specific down-regulation of the TCR z chain
expression in circulating T lymphocytes (Fig. 4, panel A).
Previous studies
It is well established that MDSCs modulate the innate and
adaptive immune responses both in cancer [11,17,23] as
well as in a variety of non-malignant conditions, including
sepsis, traumatic stress, parasitic infections [11], inflam-
matory bowel diseases [24], autoimmune disorders [16,25]
and transplantation [11,26]. Recently, increased levels of
ARG1 expressing CD11bþMHC-II myeloid cells andB) chains expression in non-smokers, smokers with normal lung
stograms of TCR z expression of a control non- smoker (black
represents the background staining of an isotype control anti-
Myeloid derived suppressor cells in COPD 1901neutrophilic MDSCs were detected in patients with pulmo-
nary hypertension and P. aeruginosa-infected cystic fibrosis
patients respectively [27,28]. Furthermore, our observation
of a specific down-regulation of TCR z chain in peripheral
lymphocytes of COPD is in keeping with previous studies in
patients with autoimmune diseases [29], chronic infection
[30], cancer[31e34] and in animal models of chronic
inflammation [35,36]. This finding is consistent with a
defective proliferative response to TCR specific activation
signals previously described in peripheral T-cells of COPD
patients [37]. To our knowledge, the role of MDSCs in COPD
has not been investigated before.
Interpretation of findings
A variety of soluble factors, including IL-6, IL-1ß, PGE2,
VEGF, GM-CSF and IFN g, have been implicated in the MDSCs
expansion and activation that occurs in cancer and other
chronic inflammation conditions [11]. Many of them are also
increased in smokers and patients with COPD [38,39] and
can thus contribute to explain our observations.
An important observation of our study was the differ-
ential response of circulating MDSCs to smoking cessation in
smoker controls and COPD patients (Fig. 2, panel B). A
similar type of response has been previously described in
smokers with and without COPD for a number of inflam-
matory mediators [39], indicating the presence of one or
more self-perpetuating inflammatory loops in COPD [3].
TheT-cell receptor (TCR) is a keymultisubunit complex for
antigenrecognition, signal transduction, andantigen-specific
immune response [29]. TheTCR z chain subunit plays a critical
role in the assembly, expression and signaling of the TCR
complex [29]. Different chronic inflammatory conditions, like
cancer, autoimmune and infectious diseases, are character-
ized by TCR z down regulation and defective T cell function
[29]. In vitro studies havedemonstrated thatMDSCsmodulate
T cell function by reducing the TCR z expression [31e34].
In vivo, in animalmodels of chronic inflammation, MDSCs also
down-regulated TCR z, resulting in an immunosuppressive
environment [35,36]. We observed that, despite similarly
increased circulating MDSCs in current smoker controls, the
expressionof TCR zwas reducedonly inCOPDpatients (Fig. 4,
panel A). We hypothesize that this can be related to the fact
that smoking induces different inflammatory response pat-
terns (inflammome) in smokers with or without COPD [39],
and that they might exert different regulatory effects [11].
Specifically, we speculate that in smokers who manage to
maintain lung function within the normal range despite their
habit, the increase in circulating MDSCs is a transient, non-
specific response, whereas in patients with COPD it is part
of an activated adaptive immune response that is unrespon-
sive to smoking cessation (Fig. 2, panel B) [3] and is charac-
terized by a specific down regulation of the TCR z in an
attempt to minimize tissue damage (Fig. 4, panel A) [4,5,29]
We think, however, that this hypothesis deserves further
research.
Potential limitations
This study has some limitations. Firstly, smokers with COPD
had a higher cumulative smoking exposure, were older thanthose with normal spirometry and were predominantly men
(Table 1). We think that these differences are unlikely to
influence our results significantly because smoking exposure
in the latter was still substantial (about 40 pack-year, which
was associated with an upregulation of MDSCs), there was no
difference in age between former smokers and COPD pa-
tients andwedid not find any significant correlation between
smoking exposure or age and circulating MDSCs in the bivar-
iate analysis. Secondly, we studied circulating MDSCs and T
lymphocytes. Thus, it is possible that the distribution of
MDSCs and the expression of TCR z in the lung parenchyma
can be different. Thirdly, we did not perform detailed
mechanistic assays, so we are aware that functional prop-
erties of MDSCs require additional studies.
Conclusions
Our study shows that smoking modulates MDSCs, that this
effect persist after quitting smoking in patients with COPD
and that in these latter patients (but not in smokers with
normal spirometry) it is associated with a significant down-
regulation of TCR z expression in circulating lymphocytes.
All in all, these results support the participation of MDSCs in
the pathogenesis of COPD.
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